Shedding Light on the Role of Exosomal PD-L1 (ExoPD-L1) in Cancer Progression: an Update.

Autor: Sun D; Siping City Central People's Hospital, Siping, Jilin, 136000, P. R. China., Altalbawy FMA; Department of Biochemistry, University College of Duba, University of Tabuk, Tabuk, Saudi Arabia. fmaaltalbawy@gmail.com., Yumashev A; Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia., Hjazi A; Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia., Menon SV; Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India., Kaur M; Department of Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India., Deorari M; Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India., Abdulwahid AS; Department of Medical Laboratories Technology, Al-Hadi University College, Baghdad, 10011, Iraq., Shakir MN; Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq., Gabal BC; Medical Laboratory Technique College, the Islamic University, Najaf, Iraq.; Medical Laboratory Technique College, the Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.; Medical Laboratory Technique College, the Islamic University of Babylon, Babylon, Iraq.
Jazyk: angličtina
Zdroj: Cell biochemistry and biophysics [Cell Biochem Biophys] 2024 Sep; Vol. 82 (3), pp. 1709-1720. Date of Electronic Publication: 2024 Jun 22.
DOI: 10.1007/s12013-024-01340-7
Abstrakt: Exosomes are the primary category of extracellular vesicles (EVs), which are lipid-bilayer vesicles with biological activity spontaneously secreted from either normal or tansformed cells. They serve a crucial role for intercellular communication and affect extracellular environment and the immune system. Tumor-derived exosomes (TEXs) enclose high levels of immunosuppressive proteins, including programmed death-ligand 1 (PD-L1). PD-L1 and its receptor PD-1 act as crucial immune checkpoint molecules, thus facilitating tumor advancement by inhibiting immune responses. PDL-1 is abundantly present on tumor cells and interacts with PD-1 on activated T cells, resulting in T cell suppression and allowing immune evasion of cancer cells. Various FDA-approved monoclonal antibodies inhibiting the PD-1/PD-L1 interaction are commonly used to treat a diverse range of tumors. Although the achieved results are significant, some individuals have a poor reaction to PD-1/PD-L1 blocking. PD-L1-enriched TEXs may mimic the impact of cell-surface PD-L1, consequently potentiating tumor resistance to PD1/PD-L1 based therapy. In light of this, a strong correlation between circulating exosomal PD-L1 levels and response rate to anti-PD-1/PD-L1 antibody treatment has been evinced. This article inspects the function of exosomal PDL-1 in developing resistance to anti-PD-1/PD-L1 therapy for opening new avenues for overcoming tumor resistance to such modalities and development of more favored combination therapy.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: